Precision Biologics, Inc. announces in vitro and in vivo efficacy of its novel tumor-specific ADC (PB-vcMMAE-5) against human carcinomas expressing truncated core 2 O-glycans. Recent data for several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results